Streamlining Highly Potent Drug Commercialization

By Norbert Straub, Director Development & Transfer Pharma, FAREVA-Excella, Fareva, Robert Klehr, Head of Pharma Sales, North America, Fareva, and Uwe Korn, General Manager, Drug Products, FAREVA-Excella, Fareva

Demand for highly potent drug substances and drug products continues to increase, driven by macro trends in the pharma industry. Both small and large pharma companies are looking to cooperate with experienced outsourcing partners with demonstrated successes and the ability to support projects from the earliest development stages through drug substance optimization, final drug product formulation, process optimization according to quality-by-design (QbD) principles, and clinical and commercial manufacturing and packaging. FAREVA is continuously investing in its high-potency capabilities for both drug substance and drug product and is well-positioned to serve clients as a one-stop shop for even the most potent compounds.